Skip to main content
All lobbying filings

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated filed a Q1 report for Vertex Pharmaceuticals Incorporated on April 17, 2026.

Lobbying for Vertex Pharmaceuticals Incorporated

As filed: VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED.

All filings by Vertex Pharmaceuticals Incorporated · Everything Vertex Pharmaceuticals Incorporated has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 17, 2026
Expenses
$1,140,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Massachusetts

Official filing document

 Lobbyists on this filing 1
  • KYLE HILL New on this filing
    Previously held: Leg. Director, Rep. Suzan DelBene (1/19-7/22); Sr. Leg. Asst., Rep. Suzan DelBene (10/17-1/19); Health Policy Advisor, Rep. Steve Israel (2/16-12/16); Leg. Asst., Rep. Steve Israel (5/13-12/14); Staff Asst., Rep. Steve Israel (12/12-05/13)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 10

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 7
Health Issues

Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.

Medicare/Medicaid

Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.

Taxation/Internal Revenue Code

Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit.

Budget/Appropriations

Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS.

Trade (domestic/foreign)

Intellectual property reforms to address unfair trade practices in Argentina and Russia.

Veterans

Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).

Defense

Issues related to the Defense Health Agency and service member access to non-opioid alternatives, including reinstating the DHA Benefits Advisory Panel and the structured formulary management process.

 Bills named in this filing 6

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem